Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week onc...

詳細記述

書誌詳細

主要な著者:	María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2014-06-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/7054
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!